Compare ARK Innovation ETF (ARKK) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Novavax Inc — how do they compare? ARK Innovation ETF trades at $81.19, while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | NVAX | |
|---|---|---|
52-Week High | $92.50 | $11.19 |
52-Week Low | $63.52 | $6.22 |
Market Cap | — | $1.31B |
Sector | — | Health |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKK trades at $81.51, up 1.3% on the day, with technical indicators showing a bullish trend from moving averages but overbought short-term RSI. The ETF's performance remains challenged by high concentration in speculative growth stocks like Tesla and SpaceX, with no fundamental ratios provided. Recent news highlights Cathie Wood's continued bets on AI and space innovation amid criticism of fees and underperformance versus the S&P 500.
Outlook is cautious due to reliance on a few volatile holdings and premium fees; risks include growth deceleration and market sentiment shifts. Opportunities exist if disruptive bets pay off, but investor patience is required amid potential downside volatility.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
